Sign In     |     Sign Up
Home / News / Medline announces first infection control product

Medline announces first infection control product

25
Jun '19
Pic: Medline
Pic: Medline
Medline’s Micro-Kill Bleach Germicidal Bleach Wipes have become the first infection control product to be cleared by EPA to kill Candida auris (C. auris), a multidrug resistant fungus, found in hospitals. The announcement solidifies Micro-Kill Bleach Germicidal Bleach Wipes’ place in Medline’s industry-leading portfolio of infection prevention products.

Medline is the first to bring to market a product approved to kill Candida auris due to the long-term planning of a team of professionals across different Medline divisions dedicated to improving healthcare infection prevention and minimising the spread of infectious diseases, said the company in a press release.

The fungus, which has a mortality rate of 35 per cent, has been shown to linger in healthcare facilities despite efforts to eradicate it with traditional disinfectants. The fungus, which can be difficult to treat, has caused outbreaks worldwide, including New York and Chicago.

After years of development and rigorous testing, EVS associates can now begin using the wipes as part of infection prevention-informed room turnovers and nurses can use them on medical equipment and high-touch surfaces.

“C. auris has emerged as a new and alarming threat, and until now healthcare providers and environmental staff (EVS) had no proven tools to combat it. What we've shown with the Micro-Kill Bleach Germicidal wipes is an effective way to disinfect hospital surfaces, where C. auris tends to be persistence in the environment. Our goal is to take a proactive approach to combating this pathogen,” said Rosie D. Lyles, MD, director of clinical affairs at Medline. “Through the collective work of Medline’s infection prevention team, we’ve developed a way to effectively reduce cross contamination of C. auris using Micro-kill bleach and proper hand hygiene.”

“As an infection-prevention solutions provider, we are dedicated to staying on top of emerging pathogens and epidemiology trends. We identified C. auris as a potential threat more than two years ago after a handful of cases started to surface. At that time, the EPA had not yet developed a method to test the pathogen. We closely monitored the progress on the EPA testing methods so that as soon as it was made available, we were one of the first in line to get our Micro-Kill Bleach wipes tested,” said Megan Henken, director of product management, Medline Textiles division.

Medline is a healthcare company: manufacturer, distributor and solutions provider focused on improving the overall operating performance of healthcare. (PC)

Fibre2Fashion News Desk – India

Leave your Comments

Pic: ZAL Center for Applied Aeronautical Research
ZAL & NRC sign agreement to expand research collaboration
Pic: Velocity Composites
Velocity to support Wesco’s product offering expansion

Follow us